Cargando…
Kidney cancer biomarkers and targets for therapeutics: survivin (BIRC5), XIAP, MCL-1, HIF1α, HIF2α, NRF2, MDM2, MDM4, p53, KRAS and AKT in renal cell carcinoma
The incidence of renal cell carcinoma (RCC) is increasing worldwide with an approximate 20% mortality rate. The challenge in RCC is the therapy-resistance. Cancer resistance to treatment employs multiple mechanisms due to cancer heterogeneity with multiple genetic and epigenetic alterations. These c...
Autores principales: | Li, Fengzhi, Aljahdali, Ieman A. M., Zhang, Renyuan, Nastiuk, Kent L., Krolewski, John J., Ling, Xiang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8359575/ https://www.ncbi.nlm.nih.gov/pubmed/34384473 http://dx.doi.org/10.1186/s13046-021-02026-1 |
Ejemplares similares
-
Cancer therapeutics using survivin BIRC5 as a target: what can we do after over two decades of study?
por: Li, Fengzhi, et al.
Publicado: (2019) -
Mutant Kras as a Biomarker Plays a Favorable Role in FL118-Induced Apoptosis, Reactive Oxygen Species (ROS) Production and Modulation of Survivin, Mcl-1 and XIAP in Human Bladder Cancer
por: Santha, Sreevidya, et al.
Publicado: (2020) -
Serdemetan Antagonizes the Mdm2-HIF1α Axis Leading to Decreased Levels of Glycolytic Enzymes
por: Lehman, Jason A., et al.
Publicado: (2013) -
Inhibition of MDM2 homodimerization by XIAP IRES stabilizes MDM2, influencing cancer cell survival
por: Liu, Tao, et al.
Publicado: (2015) -
MDM2 promotes cancer cell survival through regulating the expression of HIF-1α and pVHL in retinoblastoma
por: Zhang, Shouhua, et al.
Publicado: (2023)